Galux is a biotechnology company pioneering protein therapeutics design through its GaluxDesign platform, which uniquely combines artificial intelligence with physical principles to design proteins from first principles. The platform focuses on de novo antibody design and precision protein engineering to accelerate drug discovery. Headquartered in Seoul, Republic of Korea, Galux serves the global biopharmaceutical field with a proprietary AI-driven approach that aims to push the boundaries of protein design from discovery to development.